Literature DB >> 28291571

The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).

Sarah J Cousins1, Desirée Crèvecoeur-MacPhail2, Tina Kim3, Richard A Rawson2.   

Abstract

Extended-release naltrexone (XR-NTX) is a medication-assisted treatment (MAT) that is used in conjunction with psychosocial treatment for substance use disorder. It is associated with a reduction in the number of days that patients use alcohol or opioids, in cravings and drug-seeking behaviors, and in healthcare utilization costs, as well as improved medication adherence rates for patients in substance use disorder (SUD) treatment programs and improved quality of life. Despite the clinical effectiveness of XR-NTX, its clinical use has been slow to develop. There is little research describing the utilization of XR-NTX over time at the treatment-system level and few documented attempts to promote MAT by creating a system to explicitly promote and sustain MAT use. This study examines changes between April 1, 2010, and March 30, 2015, in the utilization patterns of XR-NTX for SUDs as promoted and delivered in a system of "medication hubs," comprised of community providers and a medication coordinating center, and training efforts. This system was implemented as part of a large demonstration project that was designed to provide access to XR-NTX in Los Angeles County. Our findings indicated an increase in the initiation of XR-NTX (59% increase) and subsequent doses (89% increase) from Year 1 to Year 5 of the project (p<0.001). These findings suggest that it is possible to improve MAT utilization (in this case XR-NTX) through the use of a system of care that minimizes MAT payment issues for providers and patients, provides an infrastructure (medication hubs and SUD treatment providers), promotes system coordination, and educates providers.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol use disorder; Extended-release naltrexone; Injectable naltrexone; Medication-assisted treatment; Opioid use disorder; SUD treatment system development

Mesh:

Substances:

Year:  2017        PMID: 28291571     DOI: 10.1016/j.jsat.2017.02.011

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  4 in total

1.  The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.

Authors:  Sharon Reif; Mary F Brolin; Maureen T Stewart; Thomas J Fuchs; Elizabeth Speaker; Shayna B Mazel
Journal:  J Subst Abuse Treat       Date:  2019-07-19

Review 2.  Opioid use disorder.

Authors:  John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh
Journal:  Nat Rev Dis Primers       Date:  2020-01-09       Impact factor: 52.329

3.  Provider perspectives on emergency department initiation of medication assisted treatment for alcohol use disorder.

Authors:  Thibault Philippine; Ethan Forsgren; Cassandra DeWitt; Inanna Carter; Maureen McCollough; Breena R Taira
Journal:  BMC Health Serv Res       Date:  2022-04-07       Impact factor: 2.655

Review 4.  Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Authors:  Virginia Perez-Macia; Mireia Martinez-Cortes; Jesus Mesones; Manuel Segura-Trepichio; Lorena Garcia-Fernandez
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.